FDA Progesterone on HVD vs Endrenyi [RSABE / ABEL]

posted by FI – Austria, 2012-03-09 14:50 (5223 d 14:28 ago) – Posting: # 8244
Views: 13,107

Dear all,

I cross-checked the L. Endrenyi/L Tothfalusi chapter in Kanfer/Shargel’s book “Generic Drug Product Development” and found a difference to the code provided by FDA for Progesterone:
The so called “x” (=PE²-SE²) in the Progesterone BE recommendation does not resemble the Em (=PE²) which would be necessary to have the identical formula for the Confidence limit calculation:

CL = Em-Es + √(Lm+Ls) acc. to your Kanfer/Shargel Chapter

I tried now to simulate data in EXCEL to find out, which one is correct and calculated a “third” way of concluding BE: simply the exponentiated CI for the difference of the means using the SE of the differences.

Instead of solving the problem, I have now 3 (slightly) differing results; This might be due to simple programming mistake but I couldn’t find them up to now;

1) Does anyone know, if there is a(nother) mistake in the FDA recommendation (the “x” as described above)?

Thanks a lot


Edit: Category changed. [Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,572 registered users;
387 visitors (0 registered, 387 guests [including 28 identified bots]).
Forum time: 06:18 CEST (Europe/Vienna)

The real struggle is not between the right and the left
but between the party of the thoughtful
and the party of the jerks.    Jimmy Wales

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5